Published in Vaccine Weekly, October 16th, 2002
"Immunization of mice with pneumococcal surface adhesin A (PsaA) emulsified in complete Freund's adjuvant (CFA) provides protection against systemic infection with Streptococcus pneumoniae," but CFA is not suitable for use with humans, explained Dennis O. Gor and colleagues at Case Western Reserve University in Cleveland.
Fusing PsaA genes with those coding for immunostimulatory cytokines produced a similar enhancement without the use of CFA although the resulting vaccine was still...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.